

Title: Authorship Policy

Version Date: 04/05/2023

POLICY:

All sites must follow the below steps when assigning authorship on abstracts or manuscripts.

PROCEDURE:

1. Any person nominated to be an author of an ARGO/GCDI research study must meet the authorship criteria of the International Committee of Medical Journal Editors (updated October 2007 – <http://www.icmje.org/>). These state: “Authorship credit should be based on: 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.” Authors will meet all three conditions.
2. More than 50% authorship should be based in the LMIC where the research originates.
3. Each center that participates in a research study will be able to nominate at least one author. Additional authors from each site will depend on the project and be determined by the PIs and ARGO leadership. We will use “on behalf of the ARGO Consortium” as the final author when possible. Authors not listed by name for a study can then be included at the end of the manuscript in a list of ARGO members and this counts towards authorship for resumes and promotions.
4. Position in the list of authors will be determined on the basis of contributions to the work.
5. The first author will be the person who has made the largest contribution to developing the study, analyzing the data and drafting the paper, or someone who has made a similar contribution and is nominated by the person who has made the largest contribution. Co-first authorship is encouraged as permitted by journal guidelines.
6. The last or senior author will generally be the chief investigator of a participant study who has made the largest contribution to developing the scientific hypothesis and project protocol, bringing together the data sets, analyzing the data and drafting the paper.



African Research Group for Oncology

7. Whenever possible it is encouraged to have open discussions about authorship early in the development of a research project and as study sites are incorporated into multi-center trials. Questions regarding authorship should be directed to ARGO/GCDI leadership.